Retinoblastoma Pharmaceutical and Healthcare Pipeline Review H2

WiseGuyReports.com adds “Retinoblastoma – Pipeline Review, H2 2016” reports to its database.

Pune, India – November 15, 2016 /MarketersMedia/ —

Retinoblastoma is an eye cancer that begins in the retina. Symptoms include white color in the center circle of the eye (pupil), eye redness, vision problems, a different color in each iris and eye swelling. The predisposing factors include age and heredity. Treatment includes chemotherapy, radiation therapy and surgery.

Get Sample Report @ https://www.wiseguyreports.com/sample-request/740548-retinoblastoma-pipeline-review-h2-2016

Report Highlights
Pharmaceutical and Healthcare latest pipeline guide Retinoblastoma – Pipeline Review, H2 2016, provides comprehensive information on the therapeutics under development for Retinoblastoma (Oncology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Retinoblastoma (Oncology) pipeline guide also reviews of key players involved in therapeutic development for Retinoblastoma and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase I and Preclinical stages are 1 and 5 respectively. Similarly, the Universities portfolio in Preclinical stages comprises 1 molecules, respectively.Retinoblastoma.

Retinoblastoma (Oncology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Scope
– The pipeline guide provides a snapshot of the global therapeutic landscape of Retinoblastoma (Oncology).
– The pipeline guide reviews pipeline therapeutics for Retinoblastoma (Oncology) by companies and universities/research institutes based on information derived from company and industry-specific sources.
– The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
– The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
– The pipeline guide reviews key companies involved in Retinoblastoma (Oncology) therapeutics and enlists all their major and minor projects.
– The pipeline guide evaluates Retinoblastoma (Oncology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
– The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
– The pipeline guide reviews latest news related to pipeline therapeutics for Retinoblastoma (Oncology)

Reasons to buy
– Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
– Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
– Find and recognize significant and varied types of therapeutics under development for Retinoblastoma (Oncology).
– Classify potential new clients or partners in the target demographic.
– Develop tactical initiatives by understanding the focus areas of leading companies.
– Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
– Formulate corrective measures for pipeline projects by understanding Retinoblastoma (Oncology) pipeline depth and focus of Indication therapeutics.
– Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
– Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Table of Contents
Table of Contents 2
List of Tables 4
List of Figures 4
Introduction 5
Retinoblastoma Overview 6
Therapeutics Development 7
Pipeline Products for Retinoblastoma – Overview 7
Pipeline Products for Retinoblastoma – Comparative Analysis 8
Retinoblastoma – Therapeutics under Development by Companies 9
Retinoblastoma – Therapeutics under Investigation by Universities/Institutes 10
Retinoblastoma – Pipeline Products Glance 11
Clinical Stage Products 11
Early Stage Products 12
Retinoblastoma – Products under Development by Companies 13
Retinoblastoma – Products under Investigation by Universities/Institutes 14
Retinoblastoma – Companies Involved in Therapeutics Development 15
BioLineRx, Ltd. 15
Cellceutix Corporation 16
Icon Bioscience, Inc. 17
Recombio S.L 18
Retinoblastoma – Therapeutics Assessment 19
Assessment by Monotherapy Products 19
Assessment by Target 20
Assessment by Mechanism of Action 22
Assessment by Route of Administration 24
Assessment by Molecule Type 26
Drug Profiles 28
BL-8040 – Drug Profile 28

Access Report @ https://www.wiseguyreports.com/reports/740548-retinoblastoma-pipeline-review-h2-2016

Get in touch:
LinkedIn: www.linkedin.com/company/4828928
Twitter: https://twitter.com/WiseGuyReports
Facebook: https://www.facebook.com/Wiseguyreports-1009007869213183/?fref=ts

For more information, please visit http://www.wiseguyreports.com

Contact Info:
Name: Norah Trent
Organization: WiseGuy Reports
Address: Office No. 528, Amanora Chambers Magarpatta Road, Hadapsar Pune – 411028 Maharashtra, India
Phone: +1-646-845-9349

Source: http://marketersmedia.com/retinoblastoma-pharmaceutical-and-healthcare-pipeline-review-h2/146305

Release ID: 146305